Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Starpharma Holdings Ltd
ABN 20 078 53	2 180

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Jacinth K Fairley
Date of last notice	19 December 2011

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		
Date of change	(i) 22-23 February 2012 (ii) 24 February 2012 (iii) 27 February 2012 (iv) 27 February 2012	
No. of securities held prior to change	 1. 1,769,197 Ordinary Shares (direct) 2. 53,750 Ordinary Shares (indirect) Dr Ian Fraser <fraser a="" c="" fairley="" super=""></fraser> 3. 375,000 Performance Rights (SPLAK) 	
Class	Ordinary Shares	
Number acquired	Nil	
Number disposed	(i) 107,463 (ii) 18,787 (iii) 23,750 (iv) 23,750 Total: 173,750	

⁺ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	(i) \$153,906 (\$1.43 per share) (ii) \$26,026 (\$1.38 per share) (iii) \$33,725 (\$1.42 per share) (iv) \$33,562 (\$1.41 per share) Total: \$247,219	
No. of securities held after change	 1,619,197 Ordinary Shares (direct) 30,000 Ordinary Shares (indirect) Dr Ian Fraser 375,000 Performance Rights (SPLAK) 	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market sale of shares to partially fund the tax liability associated with securities granted under the Company's equity incentive plans.	

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011